SCHEMBL3583177

SCHEMBL3583177

CCC1c2ccc(Cl)cc2S(=O)(=O)NN1C(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.37
CA12 O43570 2/20 0.37
CA4 P22748 2/20 0.37
CA7 P43166 2/20 0.37
CA9 Q16790 2/20 0.37
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CA1 P00915 2/20 0.35
GRIA2 P42262 5/20 0.35
GRIA1 P42261 4/20 0.35
GRIA3 P42263 4/20 0.35
GRIA4 P48058 4/20 0.35
ABCC8 Q09428 2/20 0.35
KCNJ11 Q14654 2/20 0.35
CHEK1 O14757 1/20 0.33
DAPK3 O43293 1/20 0.33
MAP4K4 O95819 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3587549 0.81 GRIA2 (0.39) CA2CA12CA4CA7CA9
SCHEMBL3575925 0.68 ALDH1A1 (0.40) CA2CA12CA4CA7CA9
SCHEMBL3588752 0.62 ALDH1A1 (0.46) CA2CA12CA4CA7CA9
SCHEMBL2791341 0.59 ALDH1A1 (0.37) CA2CA12CA4CA7CA9
SCHEMBL3578225 0.58 CA2 (0.46) CA2CA12CA4CA7CA9
SCHEMBL13532905 0.55 GRM5 (0.40) CA2CA12CA4CA7CA9
SCHEMBL23191245 0.54 GRIA2 (0.46) CA2CA12CA4CA7CA9
SCHEMBL24090541 0.54 CA1 (0.42) CA2CA1GRIA2GRIA1GRIA3
SCHEMBL10523866 0.54 CA2 (0.48) CA2CA12CA4CA7CA9
SCHEMBL24090539 0.54 CA1 (0.42) CA2CA1GRIA2GRIA1GRIA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENTARSASAG (HU) 2010-07-29 US disclosed
EP-2064197-A2 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) 2009-06-03 EP disclosed
WO-2008020256-A2 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE EGIS GYÓGYSZERGYÁR_Nyilvánosan Müködö Részvénytársaság (HU) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE TDO2, DHODH, DHPS CA2 1607/4885CA12 3434/4885CA4 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.